TON Web Exclusives

Based on results from the phase 3 FLAURA trial, the FDA has granted osimertinib (Tagrisso) breakthrough therapy designation for treatment-naïve patients with EGFR-positive non–small-cell lung cancer.
In the pivotal phase 3 KEYNOTE-189 trial of pembrolizumab (Keytruda) combined with pemetrexed and cisplatin or carboplatin for the first-line treatment of patients with metastatic, nonsquamous non–small-cell lung cancer, the regimen showed significant improvements in overall survival and progression-free survival.
The kinase inhibitor alectinib (Alecensa) received FDA approval for the frontline treatment of ALK-positive, metastatic, non–small-cell lung cancer based on results from the phase 3 ALEX trial.
Although crizotinib is the standard of care for the first-line treatment of patients with ALK-positive non–small-cell lung cancer, disease progression occurs in most crizotinib-treated patients, often calling for the use of second-generation ALK inhibitors such as alectinib, brigatinib, and ceritinib, among other treatment strategies.
Results from a phase 2 trial of lorlatinib, an investigational, next-generation tyrosine kinase inhibitor, showed efficacy in treating lung tumors and brain metastases in patients with ALK-positive and ROS1-positive advanced non–small-cell lung cancer, including those who have been heavily pretreated.
Updated data from the phase 2 ALTA trial continue to support the efficacy and tolerability of brigatinib, an oral inhibitor of anaplastic lymphoma kinase (ALK), in patients with locally advanced or metastatic ALK-positive non–small-cell lung cancer (NSCLC) who have progressed while using crizotinib.
Until the expanded approval of afatinib, no targeted treatment options were available for patients with non–small-cell lung cancer (NSCLC) who harbored rare, nonresistant EGFR mutations, such as S768I, L861Q, and G719X. Among oral tyrosine kinase inhibitors approved for use in EGFR mutation–positive NSCLC, afatinib now offers the broadest first-line indication.
In patients with stage III non–small-cell lung cancer (NSCLC) whose disease did not progress after 2 or more cycles of platinum-based chemoradiotherapy, use of durvalumab as consolidation therapy significantly improved progression-free survival.
According to the results of a recent phase 2 clinical trial, treatment with a regimen of dabrafenib, an oral BRAF inhibitor, plus trametinib, an MEK inhibitor, is effective and tolerable in previously untreated patients with BRAF V600E‒mutated metastatic non–small-cell lung cancer (NSCLC).
Rovalpituzumab tesirine, an investigational antibody-drug conjugate that targets delta-like protein 3, shows encouraging single-agent efficacy with a manageable safety profile in the treatment of patients with recurrent small-cell lung cancer, according to recently published results.
Page 1 of 5
Results 1 - 10 of 46

©2018 Green Hill Healthcare Communications, LLC, an affiliate of The Lynx Group. All rights reserved.
1249 South River Road - Suite 202, Cranbury, NJ 08512